Company Description: Celosia Therapeutics is a late discovery / early pre-clinical phase gene therapy company that is changing the paradigm for treatment for neurodegenerative disease. This is achieved by the incorporation of a novel molecular switch into our therapeutic platform that initially targets the devastating condition, Amyotrophic Lateral Sclerosis (ALS). ALS is a terminal motor neuron disease for which there remains no effective treatment. The proposed gene therapy targets pathogenic TDP43 aggregates in the cytoplasm restoring cellular proteostasis through targeted protein degradation, preventing neuronal cell death, and thus disease progression.